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t is recognized that prolonged myocardial ischemia is accompanied by a time-dependent loss of the viability of myocardial cells in the jeopardized region of the heart.' Reperfusion is necessary to initiate and maintain those functions responsible for reversal of the changes induced by ischemia and for the continued survival of the myocardial cells at risk of permanent damage. The development of pharmacologic methods for reperfusion of the ischemic heart has reduced mortality and has led to the acceptance of thrombolytic therapy as the standard approach to the management of patients with an evolving acute myocardial infarction. 2 Reperfusion injury has been recognized as occurring in experimental models of myocardial ischemia.3 It has been assumed that the observed loss of cell viability associated with the reintroduction of oxygen was solely an acceleration of cell death in myocytes that were beyond the point of salvage, or had been injured irreversibly. Reexamination of this question suggests that reperfusion of the previously ischemic heart with oxygenated whole blood may be detrimental as well as beneficial to the myocyte.4-6 A significant effort has been devoted to gaining a better understanding of the oxygen paradox7 or the phenomenon of reperfusion injury,7q8 or both, which may be more appropriately referred to as reoxygenation injury (i.e., an extension in the loss of myocardial cell viability beyond that due to the ischemic process itself). A number of recent reviews have been devoted to an examination of the question of whether reactive species of oxygen, or oxygen free radicals, contribute to the development of irreversible myocardial cell injury during the period of reperfusion.7-'0 The purpose of this essay is to focus attention on the role of the polymorphonuclear leukocyte (PMN) as a contributor to the phenomenon of reperfusion injury and to call attention to factors that modulate the inflammatory response to myocardial cell injury.
NEUTROPHIL-DEPENDENT DAMAGE TO THE ENDOTHELiUM AND CARDIAC MYOCYTE
One of the important functions of the PMN is defense of the host organism. However, during altered physiologic states, the PMN may react in a manner that leads to tissue injury. The tissue damage resulting from myocardial ischemia activates a sequence of events characterized as an inflammatory response that occurs independently of any improvement in myocardial reoxygenation. The concept we propose is that the invading leukocytes and ensuing inflammatory response contributes to the extension of myocardial cell injury adding to the irreversible cell injury from the ischemia itself. Interventions directed against the inflammatory cells and the cytotoxic products produced at the site of myocardial injury may result in a reduction in the extent of tissue damage associated with myocardial ischemia or reperfusion, or both. The circulating PMN does not interact with the normal endothelial surface of the vasculature. However, the PMN can be activated in response to stimuli arising from the ischemic insult, either from within or outside of the vascular compartment, and can be induced to undergo shape changes and ultimately to adhere to the surface of the vascular endothelium. ' ' Infiltration of the ischemic myocardium by PMNs begins within 60 minutes of the onset of regional myocardial ischemia and increases progressively after the onset of reperfusion. l 2-1 4 Neutrophils invade the region of ischemit myocardium long before the transmural progression of irreversible injury reaches the subepicardial myocardial region. 15 Reperfusion is essential to prevent further extension of ischemia-induced myocyte necrosis. In the absence of reperfusion, the slowly developing inflammatory response to tissue injury permits neutrophil-mediated injury to progress and requires 12 hours or more to become manifest by histologic examination of myocardial tissues. Factors involved in the initiation and termination of the myocardial inflammatory response are not understood in detail, but serve as an interesting target for the development of new therapeutic interventions to prevent extension of tissue injury, either during the ischemic period or shortly after reperfusion.
A number of studiesgel have demonstrated that interventions that limit neutrophil function or interfere with the cytotoxic factors produced by the infiltrating phagccytic cells can reduce ultimate infarct size in experimental animals that have undergone a period of regional myocardial ischemia followed by reperfusion. The role of the neutrophil as a contributor to myocardial injury in response to ischemia was suggested initially in 1975.17 Direct studies have demonstrated that ultimate infarct size was reduced by 43% in the canine heart under conditions of neutropenia, compared with control animals subjected to 90 minutes of regional myocardial ischemia followed by reperfusion for 6 hours.5 This observation subsequently was confirmed by other investigators using alternative means of inducing neutropenia. 6 Additional support for the concept of neutrophil-mediated myocardial injury is derived from the pharmacologic modulation of neutrophil function during myocardial ischemia and reperfusion. Recognition of the mechanism of protection provided by ibuprofen on experimental myocardial injury was an important step in addressing the role of the neutrophil in promoting reperfusion injury. Ibuprofen, in contrast to other inhibitors of cyclooxygenase, such as indomethacin and aspirin,'*,'9 possess myocardial protective properties without altering myocardial blood flow or the relationship between myocardial oxygen supply and demand.20,2' A review of several studies indicated that of the nonsteroidal anti-inflammatory agents examined, only ibuprofen reduced neutrophil infiltration to the reperfused myocardium. This observation suggests that the PMN contributes to the extension of tissue injury on reperfusiorGJj and is in keeping with the original lindings of Hill and Ward.17 Neither aspirin nor indomethatin reduced infarct size or the in vitro neutrophil respiratory burst in response to stimulation of the PMN with Csa. Ibuprofen, however, prevented the complement induced activation of the PMN and the production of oxygen radicals. 19 It is possible to conclude that ibuprofen, a nonsteroidal anti-inflammatory agent, does not exert its protective effect on the myocardium through inhibition of the cyclooxygenase pathway of arachidonic acid metabolism, or by altering factors that restore the balance between myocardial oxygen supply and demand.
Additional evidence for the role of the PMN as a mediator of reperfusion injury was obtained from studies in which prostacyclin, or a related analog, iloprost, as well as prostaglandin E', limited ultimate infarct size in a canine model of regional ischemia and reperfusion. The mechanism of action was attributed to the ability of the prostanoids to inhibit the formation and release of neutroPhil-derived cytotoxic metabolites of oxygen.22m24 Evidence from a number of studies indicates that the pharmacologic inhibition of neutrophil function correlates with the observed beneficial effects on myocardial reperfusion injury.
CHEMOTACTIC FACTORS AND THE ACTIVATION AND RECRUITMENT OF NEUTROPHILS
The complement system serves as one of the most important sources of inflammatory mediators involved in the acute inflammatory response. Complement activation generates a potent neutrophil chemotactic factor, CS,. This anaphylatoxin has a role in the recruitment of PMNs to the site of tissue injury and in their activation. Proteolytic enzymes from the plasma and cellular sources react with individual complement components resulting in the localized formation of inflammatory mediators, without causing a generalized activation of the complement cascade. The presence of a tissue protease in the ischemic myccardium was suggested initially as being involved in cleaving the third component of complement into chemotactically active fragments that may stimulate the attraction of neutrophils to the myocardium.25,26 Cardiac lymphatic drainage from the ischemic myocardium contains molecules of mitochondrial and subcellular origin that are bound to Cl,, which may activate the complement cascade, promote the release of leukotactic anaphylatoxins, and stimulate the migration of PMNs to sites of tissue injury. 27 Depletion of complement with cobra venom factor significantly reduced PMN intiltration into ischemic myocardium and resulted in a decrease in tissue injury associated with regional ischemia and reperfusion. 25,28 Complement-derived products can exacerbate ischemic tissue injury and cardiac dysfunction through mechanisms that are independent of the presence of neutrophils. Neutrophil-independent injury by complement may be associated with the vascular actions of the Cja, Cda and C&, known to enhance vascular permeability and alter vessel tone. Furthermore, tissue injury may be a consequence of the formation of cytolytic membrane attack complex (C5b.9), which can result in the production of transmembrane channels and facilitate the influx of extracellular calcium and disruption of myocyte function.29 THE Endothelial cells may be an important source of a specific neutrophil chemotactic factor.30 Either interleukin-l (IL-l) or tumor necrosis factor a (TNF-a) will induce, in endothelial cells, the synthesis and secretion of a neutrophil chemotactic factor similar in structure to a human monocyte-derived neutrophil-activating factor. Neutrophil-activating factor will promote neutrophil chemotaxis and, in addition, will induce an increase in intracellular calcium, an oxidative burst, and granule exocytosis through a guanosine triphosphate-binding proteindependent pathway. Similar responses are observed with other chemotactic peptides (e.g., &, formyl-methionylleucyl-phenylalanine). 31 The role that endothelial cellderived mediators may play in activating neutrophils after ischemic injury has not been investigated. These relationships are important in determining the mechanisms that initiate the activation of circulating neutrophils and promote their adherence to the injured vascular wall.
ADHERENCE-PROMOTING CELL SURFACE GLYCOPROTEIN COMPLEXES AND THE INTERACTION BEIWEEN THE GRANULOCYI'ES AND ENDOTHELIAL CELLS
Granulocytes migrate across the vascular endotheliurn into the extravascular space in response to tissue Distinct stimuli mobilize Mol from intracellular sites and lead to its expression on the cell surface. Mol participates in adherence of the leukocyte to the endothelial cell and to other PMNs, as well as in chemotaxis and spreading on cell surfaces. An increase up to twofold in Mol cell-surface expression has been observed. At least 50% of the total population of Mol receptors is located intracellularly. The increased expression of Mol increases neutrophil adherence to cell surfaces and facilitates chemotaxis. The increase in Mol glycoprotein expression is coupled to the release of neutrophil gelatinase which participates in the degradation of connective tissue, thus allowing for the passage of neutrophils through capillary walls and into the extravascular space. The up-regulation of Mol, for which C3bi serves as the ligand, would allow for enhanced recognition and attachment to endothelial surfaces that have been "opsonized." Injury to the endothelium from ischemia and reoxygenation promotes neutrophil adherence to the cell surface. There is enhanced binding of neutrophils to endothelial surfaces secondary to the interaction of neutrophil CD 18 molecules with the intercellular adhesion molecule-l (ICAM-1) on the endothelial cell membrane.32 Enhanced ICAM-expression on the endothelial cell surface can be induced by multiple inflammatory mediators including bacterial endotoxin and the cytokines IL-l, interferon-y, and TNFa.33 A distinct endothelial leukocyte adhesion molecule (ELAM-1) that promotes neutrophil binding to the endothelium can be induced by specific cytokines.34 Whether a similar increase in the expression of ELAM-1, ICAM-1 or ICAM-l-like molecules occurs in ischemic endotheliurn is not known, but may play an important role in leukocyte localization to ischemic myocardium (Fig. 1) .
It has been observed that specific cytokines will induce synthesis and secretion of a neutrophil chemotactic factor by endothelial cells. This observation and studies cited provide further evidence for an active role of the endothelial cell in modulating neutrophil activation and recruitment to ischemic tissues, rather than a "passive" participant in the interaction of inflammatory cells with the vascular wall. The interaction between endothelial cells and PMNs is required for an effective chemotactic response and for some forms of neutrophil-mediated vascular injury. This represents an important initial step in the sequence of events associated with the acute inflammatory response. A variety of agonists involved in acute inflammation, including thrombin, platelet-activating factor and leukotriene Cd, are known to facilitate the adherence of neutrophils to the endothelial surface.
The neutrophil CD1 8 glycoprotein molecules may participate in other functions beside cell adhesion and chemotaxis. The glycoproteins may be important in the transduction of signals from the cell surface to intracellular enzymatic regulatory systems as suggested by the presence of an extensive intracellular domain providing sites for interaction with cytoplasmic proteins and cytoskeletal elements.
Monoclonal antibodies, specific for either the a! or p subunits of Mel, inhibit certain neutrophil/monocyte functions, such as the binding of C3bi-opsonized particles, and adhesive interactions of neutrophils and monocytes, including neutrophil aggregation, monocyte/neutrophil adhesion and spreading on substrates (including vascular endothelium), and chemotaxis. The leukocytes of patients who are genetically deficient in their expression of the Mol glycoprotein exhibit an impairment of C3bi-particle binding and leukocyte adhesive interactions. The Mol glycoprotein has a domain that functions as the plasma membrane receptor for C3bi(CR3). The critical role of neutrophil glycoprotein adhesive receptors Mol in the inflammatory response of activated neutrophils is illustrated by the inhibitory effect of specific monoclonal antibodies on neutrophil-mediated endothelial cell injury in a rat lung model of adult respiratory distress syndrome35 and neutrophil-dependent vascular injury in skin. 36 A monoclonal antibody (904) that binds to the Mol leukocyte cell adhesion-promoting glycoprotein CD1 1 b/ CD1 8 was administered to open-chest anesthetized dogs 45 minutes after the induction of regional myocardial ischemia. Ischemia was produced by occluding the left circumflex coronary artery for 90 minutes followed by reperfusion for 6 hours. There was no difference between control and antibody-treated groups with respect to arterial blood pressure, heart rate or coronary blood flow. Administration of antibody produced no observable effect on circulating neutrophil counts demonstrating that antibody-bound neutrophils were not cleared from the circulation. Myocardial infarct size, expressed as a percentage of the area at risk of infarction, was reduced by 46% with anti-MO1 treatment. The area at risk of infarction was similar between groups. Accumulation of neutrophils within the myocardium was reduced significantly with anti-MO1 treatment.37*38 Similar protective effects were obtained in subsequent studies with anti-MO1 F(ab')2 fragments in which antibody treatment was maintained for 48 hours into the reperfusion period and infarct size was determined at 72 hours after reperfusion. Figure 2 summarizes the results from studies in which treatment with anti-MO1 antibody was associated with a significant protective effect regardless of whether infarct size was determined after 6 or 72 hours of reperfusion. Furthermore, regional myocardial blood flow determinations indicated that both groups had equal degrees of ischemia in the inner two-thirds of the myocardium during the period of coronary artery occlusion. Results with the anti-MO1 antibody indicated that the adhesive interactions of the neutrophil played a central role in neutroPhil-mediated damage and that inhibition of neutrophil adhesive interactions can reduce the extent of irreversible myocardial damage associated with reperfusion. The results are in accord with earlier studies in which myocardial reperfusion injury was reduced by a variety of interventions that shared one common property; i.e., they altered the ability of the neutrophil to react with its target tissue, the ischemically altered myocardial ce11. 24, [39] [40] [41] The relative contribution of Mol, LFA-1 and pl50,95 to leukocyte endothelial adhesion is dependent on the applied stimulus and the particular inflammatory cell involved. Monocytes and granulocytes employ distinct subunits of the adhesion-promoting glycoproteins when they interact with the vascular endothelium. Mel, as well as LFA-1 and pl50,95, molecules have been shown to be involved in leukocyte-endothelial cell adhesion. The adhesion may be prevented by antibodies directed against the specific portion of the heterodimeric surface molecules. 42 IL-1 permitted each of the subunits to contribute to granulocyte adhesion. 42 Current data suggest that the (Y subunit of each of the 3 heterodimers contains a common region in the extracytoplasmic domain which mediates the interaction of the leukocyte with the endothelial cell or with the subendothelial structures during transmigration of leukocytes to regions of tissue injury and inflammation. The data demonstrate that inhibition of neutrophil adhesion reduced the extent of myocardial reperfusion injury and are in keeping with the proposition that neutrophils serve an important role as mediators of inflammation, extending myocardial injury beyond that caused by the ischemic process itself. The data also support the hypothesis that a significant number of myocardial cells at risk are viable after a 90-minute ischemic period, but then progress to an irreversible state of injury on reperfusion with the continued accumulation of PMNs. Studies from this laboratory 43 have identified a specific "time window" in which neutrophils participate in the extension of myocardial infarction after ischemia and reperfusion. The inhibition of neutrophil activation and accumulation in the myocardium over a prolonged period of time (>48 18 1 THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 65 hours) is necessary to ensure a beneficial effect on the ultimate extension of irreversible myocardial injury. Interventions that have limited pharmacologic half-lives, while effective over brief periods of observation, may not show protective benefits if given in a single initial dose when infarct size is assessed at a period far removed from the point of administration of the treatment under study. Consideration must be given to the pharmacokinetic properties of selected interventions along with the dynamic and progressive nature of myocyte injury. The failure to consider the time course of events in myocardial ischemic and reperfusion injury may account for the discordant results in published reports. To date, published reports have failed to document a consistent progression of cellular injury attributable to the period of reperfusion and distinct from the progressive cell death entirely attributable to the period of ischemia.
NEUTROPHILS, OXYGEN RADICALS, MYOCARDIAL INJURY AND PROTECTION BY FREE RADICAL SCAVENGERS
Under some conditions of regional myocardial ischemia and reperfusion, neutrophils adhere to the vessel wall at sites of inflammation and release toxic products capable of damaging the adjacent endothelium and myocytes within the reperfused region. It is recognized that neutrophils can release cytotoxic products extracellularly without undergoing destruction themselves. Neutrophils can release a variety of mediators capable of promoting tissue injury, including proteolytic enzymes, platelet-activating factor, arachidonic acid metabolites and activated species of oxygen. The last mentioned group of neutroPhil-derived products, superoxide anion (O-Z), hydrogen peroxide (H202), hydroxyl anion (*OH) and hypochlorous anion (OCl-) are significant cytotoxic products derived from the metabolism of molecular oxygen on perturbation of the PMN. The generation of cytotoxic metabolites of oxygen, generated within the microenvironment formed between the adherent activated PMNs and altered endothelial cells, leads to an increase in vascular permeability and myocyte damage. This situation is "explosive" on reperfusion as neutrophils are directed and attracted to the reperfused region under the influence of the local accumulation of chemoattractants. During an extended period of regional ischemia of 240 minutes,14 the stage is set for the neutrophil-mediated inflammatory response and injury that involves normal or reversibly injured cells and is accelerated by reperfusion of the ischemit region. Reperfusion injury, therefore, involves cells that were viable or recoverable up until the time that reperfusion was instituted. The extension of cell death, on reperfusion of the ischemic myocardium, is mediated by the neutrophil-derived cytotoxic products of oxygen metabolism. In the absence of reperfusion, all cells that are ischemic for a sufficiently long period will undergo irreversible changes, and reperfusion is essential for survival of the myocytes that are viable up until the time of reperfusion. However, a portion of the still viable myocardial cells will undergo further injury due to the cytotoxic actions of the reactive species of oxygen.
Jolly et a144 were the first to provide evidence for the in vivo participation of oxygen radicals in myocardial reperfusion injury. They demonstrated that the administration of superoxide dismutase (SOD) plus catalase to anesthetized dogs, subjected to a 90minute interval of regional myocardial ischemia followed by reperfusion, reduced ultimate infarct size when the scavenger enzymes were administered either before the induction of regional myocardial ischemia or 15 minutes before myocardial reperfusion. However, the enzymes were without beneficial effect if they were infused 40 minutes after reperfusion had been instituted. The data suggested that an extension of myocardial injury, in addition to that associated with the ischemia-induced myocardial cell death, occurred very early in reperfusion, and myocyte damage was attenuated by pretreatment with appropriate antioxidants. Subsequent studies have demonstrated that SOD, without the addition of catalase, was equally effective in preventing the extension of myocardial injury, thereby implicating superoxide anion as the primary mediator of the myocardial damage associated with reperfusion. The relatively short pharmacologic half-life (6 to 10 minutes) of SOD is a drawback to the study of the scavenger in experimental protocols that are extended several days after reperfusion. Neutrophil chemoattraction to the ischemically injured myocardium and the local formation of neutrophil-derived reactive species of oxygen will continue to effect a cytotoxic influence on the viable myocardial cells in the reperfused tissue. The free radical-induced injury is initiated on reperfusion and continues until mechanisms, still to be elucidated, bring about a cessation of the inflammatory response.
Disagreement regarding the cardioprotective role of SOD may relate to the use of different durations for induction of ischemic injury and reperfusion. To investigate this concept we undertook studies that used a modified form of SOD in which the enzyme was conjugated to polyethylene glycol (PEG-SOD). 45 The conjugated form of SOD has a pharmacologic half-life of 30 hours. Significant plasma SOD activity was demonstrated in the dog up to 7 days after a single intravenous administration of 1,000 U/kg of PEG-SOD. Two protocols, differing in the mode of administration and duration of the reperfusion interval, were used. Dogs were subjected to occlusion of the circumflex coronary artery for 90 minutes, then reperfused for either 6 hours (protocol A) or for 4 days (protocol B). The dogs received either PEG conjugated to albumin (PEG-ALB) or PEG-SOD, 1,000 U/kg. In protocol A, treatment was administered starting 15 minutes before coronary artery occlusion and continued for 2 hours, terminating 15 minutes after reperfusion. Infarct size was determined 6 hours later. In protocol B, the conjugated proteins were given 15 minutes before reperfusion and ended simultaneously with reperfusion. Infarct size was measured after 4 days. A significant reduction in myocardial infarct size, expressed as a percent of the area at risk, was observed in protocol A in the group of dogs that received PEG-SOD compared with the PEG-ALB-treated controls. Likewise, in the extended protocol, in which infarct size was determined 4 days after reperfusion, the PEG-SOD-treated group had a significant reduction in ultimate infarct size (Fig. 3) . Hemodynamic variables did not differ during the period of coronary artery occlusion. The respective collateral blood flows to the inner two-thirds of ischemic myocardium, determined 60 minutes after occlusion, did not differ between the groups. Infarct size was inversely related to collateral blood flow in the PEG-ALB-treated group. The regression line describing the relationship between the extent of irreversible myocardial injury and collateral blood flow was shifted downward (analysis of covariance, p = 0.01) in the group of dogs treated with PEG-SOD. With use of the mean collateral blood flow to the inner two-thirds of the ischemic myocardium as a covariate, infarct size, expressed as a percentage of the area at risk, was smaller for the PEG-SOD-treated group than for the PEG-ALB-treated group (p <0.05). The data demonstrated that PEG-SOD achieved a reduction in ultimate infarct size when quantitation of myocardial injury was performed after 4 days of reperfusion, a time when the plasma SOD activity was maintained well above that found in the PEG-ALB control group. These data are consistent with studies cited which demonstrated the necessity to suppress neutrophil function up to 48 hours to effect and maintain a reduction in infarct size determined at 72 hours.43 These observations support the hypothesis that a critical "time window" exists during which antineutrophil or antioxidant therapy, or both, must be maintained to effect a reduction in the ultimate extent of the infarcted myocardium after periods of ischemia and reperfusion. PEG-SOD may have efficacy over that of the native enzyme because of its continued presence in the circulation and its ability to adhere to the surface of the vascular endothelium. PEG conjugation of SOD enhances cell association and uptake of the enzyme in a manner that renders the vascular endothelium more oxidant resistant. The vulnerability of the endothelium to injury from reactive species of oxygen may be related to a number of factors, which include anatomic proximity to activated and invading inflammatory cells and localization of xanthine oxidase activity within endothelial cells. Vascular endothelial cells subjected to an ischemic equivalent of anoxic incubation followed by reoxygenation become effective generators of oxygen free radicals as determined by electron paramagnetic resonance measurements with a spin trap agent, 5,5-dimethyl-l-l-pyrroline-l-oxide.46 SOD or catalase abolished the radical signal, suggesting that oxygen is sequentially reduced from 02 to Hz02 to *OH. Attenuation of the free radical signal by oxypurinol suggested that xanthine oxidase was a major source of the superoxide anion. It is conceivable that on reperfusion of the ischemic myocardium, the endothelial cells, as well as the adherent and infiltrating neutrophils, may provide the initial source of cytotoxic species of reduced oxygen and that the subsequent inflammatory process, involving the continued migration and accumulation of PMNs to the 20 1 THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 65 injured myocardium, provides a sustained source of oxygen radicals that diminish with time as reparative processes occur.
Interpretation of data based on inhibition of free radical production by pharmacologic inhibition of xanthine oxidase are cautioned. Recent data suggest that the rate of conversion of the dehydrogenase form of the enzyme to the oxidase form, in the rat heart, is too slow to account for the observed results.47 It has been reported that allopurinol scavenges *OH at rates comparable to those of mannitol.4s Oxypurinol, the active metabolite of allopurinol, is more effective as a scavenger of *OH. Time-dependent formation of the active metabolite in animals pretreated with alIopurino1 may explain the failure of some investigators 49 to observe a protection of the ischemic myocardium when the drug was evaluated acutely, as opposed to studies in which a pretreatment regimen was used permitting accumulation of the metabolite, oxypurinol, in which a reduction in ultimate infarct size was reported.so~51 Furthermore, oxypurinol combines with the myeloperoxidase-derived oxidant, hypochlorous acid, preventing the latter from inactivating cul-protease inhibitor and thereby protecting inflamed tissues from the damaging effects of elastase.48
OTHERFREERADICALSCAVENGERS IN THE PREVENTION OF MYOCARDIAL REPERFUSION INJURY
Previous studies have shown that sulfhydryl-containing compounds, including mercaptoproprioyl glycine (MPG), are capable of reacting with free radicals and inhibiting their biologic effects.52g53 Mitsos et aP4 reported the in vitro free radical-scavenging effects of MPG, as well as its potential to reduce myocardial infarct size in the canine heart subjected to 90 minutes of regional ischemia followed by 6 hours of reperfusion. The free radical scavenger was effective when administered intravenously just before the onset of reperfusion, suggesting that the sulfhydryl compound protects against that component of myocyte injury associated with reperfusion. Related observations regarding the cardioprotective effects of MPG have been provided by other investigators who have examined the phenomenon of myocardial stunning. It was noted that SOD, as well as MPG, were equally effective in restoring regional contractile function to the heart made ischemic for a brief period (15 minutes) followed by reperfusion.s5,56 The administration of the scavengers was effective when given before the onset of ischemia or immediately before reperfusion. If administration was delayed after the start of reperfusion, no benefit was demonstrated. These findings are reminiscent of the initial studies with SOD4 in which salvage of myocardial tissue was accomplished only if the scavenger had been given before the onset of reperfusion.
The recognition that sulfhydryl-containing compounds could scavenge oxygen free radicals and provide a degree of protection against myocardial reperfusion injury and myocardial stunning led Westlin and Mullanes7 to explore the cardioprotective actions of other sulfhydrylcontaining compounds. Several angiotensin-converting enzyme (ACE) inhibitors were examined for their ability to suppress superoxide anion formation in vitro and to improve postischemic cardiac function in vivo in a canine model of regional myocardial ischemia and reperfusion. Three sulfhydryl-containing ACE inhibitors, captopril, its stereoisomer SQ 14,534, and an analog, zofenopril (SQ 27,703) were compared with enalaprilat and teprotide. The latter 2 agents lack the sulfhydryl group, but inhibit ACE. Two additional sulfhydryl-containing compounds, MPG and N-acetylcysteine (NAC), which are not ACE inhibitors, were studied for suppression of free radical formation in vitro. The autooxidation of epinephrine to adrenochrome is mediated by superoxide anions and was inhibited by captopril, SQ 14,534, and zofenopril, with similar IC50 values of 8 to 10 PM, but not enalaprilat or teprotide (ICss greater than 1,000 PM). The autooxidation reaction is inhibited as well by MPG and NAC. Captopril, MPG or NAC, but not teprotide or enalaprilat, were shown to scavenge superoxide anion production by the purine-xanthine oxidase reaction and by canine-activated neutrophils. Therefore, captopril scavenges superoxide anions in vitro independent of an action on ACE, an action that is most likely related to the presence of a sulfhydryl moiety. Pretreatment of dogs with captopril, intravenously (5 mg/kg), before occlusion of the coronary artery for 15 minutes followed by reperfusion resulted in a 40 to 60% return to active shortening within 60 minutes of reperfusion. However, equihypotensive doses of enalaprilat did not improve segmental function during reperfusion. Dogs given captopril immediately before restoring coronary blood flow had a similar return of function as that observed in dogs treated with the drug before occlusion. SQ 14,534, the isomer of captopril, which is loo-fold less potent as an ACE inhibitor, but equipotent in scavenging superoxide anions, also improved reperfusion-induced cardiac dysfunction when administered at reperfusion (5 mg/kg). Captopril improved postischemic contractile derangements by a mechanism independent of ACE inhibition. Restoration of blood supply to the ischemic myocardium provoked ventricular fibrillation in 37.5% of control dogs, but in only 9% of those administered enalaprilat and 0% of captopril-treated dogs. SQ 14,534 did not reduce the incidence of ventricular fibrillation (40%), indicating that the antifibrillatory actions may be related to ACE inhibition, or to a direct effect of the free radical scavenger on the integrity of the coronary vascular endothelium and the preservation of regional coronary artery blood flow.
CONCLUSIONS
Regardless of the cellular site of generation (endothelial cell, neutrophil or other cellular loci), the role of reactive species of oxygen in mediating cellular injury associated with reperfusion has gained wide support through a number of studies that have been reviewed recently.58-61 These studies have not always been in agreement with the concept that reperfusion of the ischemit myocardium may result in an extension of injury beyond that which has resulted from the ischemic insult itself. We have concluded that the failure to obtain agreement among laboratories is related to differences in the models used with respect to the instrumentation of the heart in chronic animal studies, the duration of occlusion (40 vs 90 minutes), and the duration of reperfusion (6 hours vs 4 days). 43 The pharmacokinetic properties of interventions used to modify the extent of reperfusion injury must be given special consideration because the neutrophil-mediated component of reperfusion injury may be operative for several days.46 Studies reporting negative effects with native SOD may be related to the short half-life of its free radical-scavenging capacity, which compromises the chances of observing a protective effect after 4 days of reperfusion.45 This concern is applicable to other interventions studied in animal models in which assessment of efficacy is made several days after cessation of the treatment regimen. Because the PMN is implicated as being a major contributor to the observed injury on reperfusion, it is essential that the applied stimulus (ischemia) required for the ultimate chemoattraction of the PMN to the reperfused region be of sufficient duration. Short ischemic intervals (40 minutes), as opposed to longer (90 minutes) times of ischemic injury, may not serve as a sufficient stimulus for neutrophil recruitment,14 thus making it unlikely that interventions designed to mitigate against the deleterious effects of neutrophil-dependent cytotoxic products will manifest their therapeutic effect. 62 The time-dependent relationship between the duration of regional myocardial ischemia and the manifestation of reperfusion injury has been suggested by the study of Eng et aF3 and must be taken into consideration in the design of an experimental protocol for the study of reperfusion injury and its modification by pharmacologic interventions. The ability of infarct expansion to develop late in the reperfusion period must THE AMERICAN JOURNAL OF CARDIOLOGY MAY 22, 1990 21 I
